Skip to main content

Articles

Page 6 of 8

  1. Retroperitoneal fibrosis (RPF) is characterized by the proliferation of fibrous tissue in the retroperitoneum. The majority of RPF cases are due to idiopathic or IgG4-related disease. Recent studies on IgG4-re...

    Authors: Veronika Boyeva, Hatim Alabsi, Michael A. Seidman, Ryan Paterson, Jason Kur, Luke Y. C. Chen, Silvia D. Chang and Mollie Carruthers
    Citation: BMC Rheumatology 2020 4:40
  2. Patients treated for cancer with immune checkpoint inhibitors (ICI) may develop autoimmune adverse events, including ICI-induced inflammatory arthritis (IA). ICI-induced IA treatment requires balancing immune ...

    Authors: Laura C. Cappelli, Suzanne M. Grieb, Ami A. Shah, Clifton O. Bingham III and Ana-Maria Orbai
    Citation: BMC Rheumatology 2020 4:32
  3. To gain insight in the use of current systemic sclerosis (SSc) care provided by health professionals from the patient perspective. We focused on referral reasons, treatment goals, the alignment with unmet care...

    Authors: Juliane K. Stöcker, Madelon C. Vonk, Frank H. J. van den Hoogen, Maria W. G. Nijhuis-van der Sanden, Julia Spierings, J. Bart Staal, Ton Satink and Cornelia H. M. van den Ende
    Citation: BMC Rheumatology 2020 4:43
  4. Dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs) is performed to achieve steady state drug concentrations earlier after treatment start comp...

    Authors: Gerlienke E. Geurts-Voerman, Lise M. Verhoef, Bart J. F. van den Bemt and Alfons A. den Broeder
    Citation: BMC Rheumatology 2020 4:37
  5. Previous studies have linked rheumatoid arthritis (RA) risk and disease activity with vitamin D-deficiency (low serum 25-hydroxyvitamin D (25OHD)), but a causal role for vitamin D in RA is still unclear, with ...

    Authors: Stephanie R. Harrison, Gurpreet Jutley, Danyang Li, Ilfita Sahbudin, Andrew Filer, Martin Hewison and Karim Raza
    Citation: BMC Rheumatology 2020 4:38
  6. Line blot immunoassays (LIA) for myositis-specific (MSA) and myositis-associated (MAA) autoantibodies have become commercially available. In the largest study of this kind, we evaluated the clinical performanc...

    Authors: Fergus To, Clara Ventín-Rodríguez, Shuayb Elkhalifa, James B. Lilleker and Hector Chinoy
    Citation: BMC Rheumatology 2020 4:28
  7. Inflammatory Arthritis is characterized by lifelong medical treatment and an unpredictable trajectory because of the fluctuating nature of the diseases. Proactive disease management is recommended, which inclu...

    Authors: Bianca Bech, Jens Jørgen Lykkegaard, Tine Lundbak, Heidi Morsø Schrøder, Line Mette Birkeland, Mette Lund Schlyter, Lotte Hanne Hansen, Lillian Dalsgaard and Bente Appel Esbensen
    Citation: BMC Rheumatology 2020 4:44
  8. Immune-mediated necrotising myopathy (IMNM) is characterised by severe muscle weakness and necrosis with a paucity of inflammation on muscle biopsy. Around 60% of cases are associated with antibodies to the si...

    Authors: Rhys Thomas, Su-Ann Yeoh, Rupert Berkeley, Andrew Woods, Mike Stevens, Silvia Marino and Aleksandar Radunovic
    Citation: BMC Rheumatology 2020 4:29
  9. It is plausible that optimal cardiovascular disease (CVD) risk management differs in patients with rheumatoid arthritis (RA) from low or middle income compared to high income populations. This study aimed at p...

    Authors: Ahmed Solomon, Anne E. Stanwix, Santos Castañeda, Javier Llorca, Carlos Gonzalez-Juanatey, Bridget Hodkinson, Benitha Romela, Mahmood M. T. M. Ally, Ajesh B. Maharaj, Elsa M. Van Duuren, Joyce J. Ziki, Mpoti Seboka, Makgotso Mohapi, Barend J. Jansen Van Rensburg, Gareth S. Tarr, Kavita Makan…
    Citation: BMC Rheumatology 2020 4:42
  10. Disease-modifying antirheumatic drugs (DMARDs) have transformed the treatment of numerous autoimmune and inflammatory diseases but their perceived risk of harm may be a barrier to use.

    Authors: Hiba EL Masri, Samantha A. Hollingworth, Mieke van Driel, Helen Benham and Treasure M. McGuire
    Citation: BMC Rheumatology 2020 4:27
  11. The idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune conditions of skeletal muscle inflammation and weakness. MicroRNAs (miRNAs) are short, non-coding RNA which regulate gene expression o...

    Authors: Joanna E. Parkes, Anastasia Thoma, Adam P. Lightfoot, Philip J. Day, Hector Chinoy and Janine A. Lamb
    Citation: BMC Rheumatology 2020 4:25
  12. Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis ...

    Authors: Shubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, Firdaus Fatima, Vamsi Krishna Bandi, Pankaj Thakur, Bala Reddy, Sreenivasa Chary, Leela Talluri, Ajay Gupta, Amit Ramchandra Kale, Anil Kumar Gupta, Ashok Kumar P, Diwakar Reddy, Younus Mohammed, Soma Shekar…
    Citation: BMC Rheumatology 2020 4:24
  13. Patients with inflammatory arthritis (IA), defined as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), are at increased risk for cardiovascular disease (CVD). The frequency of screening and treatment o...

    Authors: Iris Navarro-Millán, Sarah R. Young, Sally Shurbaji, Chastity McDavid, Anna Cornelius-Schecter, Bernadette Johnson, Andrea L. Cherrington, Liana Fraenkel, Susan M. Goodman, Jeffrey R. Curtis, Shilpa Venkatachalam and Monika M. Safford
    Citation: BMC Rheumatology 2020 4:26
  14. In this commentary, we discuss the potential of advanced imaging, particularly Dynamic Contrast Enhanced (DCE) magnetic resonance imaging (MRI) for the objective assessment of the inflammatory process in rheum...

    Authors: Ali Mobasheri, Mark Hinton, Faiq Shaikh and Olga Kubassova
    Citation: BMC Rheumatology 2020 4:33
  15. Osteoarthritis (OA) is a progressive, chronic disease characterized by articular cartilage destruction. The pro-inflammatory cytokine IL-17 levels have been reported elevated in serum and synovial fluid of OA ...

    Authors: Dovile Sinkeviciute, Anders Aspberg, Yi He, Anne-Christine Bay-Jensen and Patrik Önnerfjord
    Citation: BMC Rheumatology 2020 4:30
  16. Severe spinal pain is an unusual presentation of gout. Due to its rarity and the difficulty of obtaining joint fluid or tissue for crystal analysis, dual energy computed tomography (DECT) may be a useful imagi...

    Authors: Jeremy X. Wang, Beverly Ng, Haesung Bak, David Spencer, Nicholas Manolios and Peter K. K. Wong
    Citation: BMC Rheumatology 2020 4:22
  17. Various inflammatory conditions may present with musculoskeletal symptoms similar to those of polymyalgia rheumatica (PMR). We investigated findings on 18F-fluorodexoxyglucose (FDG)-positron emission tomography/c...

    Authors: Hideyuki Horikoshi, Takashi Nakanishi, Katsumi Tamura, Fumihiko Kimura and Kenji Itoh
    Citation: BMC Rheumatology 2020 4:21
  18. Despite contemporary advances in understanding pathogenesis and effective management of gout, beliefs about the disease continue to be focused on gout as a self-inflicted illness. The illness label itself may ...

    Authors: Nicola Dalbeth, Meihana Douglas, Kate MacKrill, Leanne Te Karu, Maria Kleinstäuber and Keith J. Petrie
    Citation: BMC Rheumatology 2020 4:23
  19. Conservative, first-line treatments (exercise, education and weight-loss if appropriate) for hip and knee joint osteoarthritis are underused despite the known benefits. Clinicians’ beliefs can affect the advic...

    Authors: Daniel W. O’Brien, Sandra Bassett, Valerie Wright-St Clair and Richard J. Siegert
    Citation: BMC Rheumatology 2020 4:15
  20. Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn’s disease and ulcerative c...

    Authors: David P. Hudesman, Soumya D. Chakravarty, Bruno Emond, Lorie A. Ellis, Patrick Lefebvre, Kay Sadik and Jose U. Scher
    Citation: BMC Rheumatology 2020 4:16
  21. Rheumatoid arthritis is the most common type of inflammatory arthritis affecting about 1% of the population. With the advent of disease-modifying anti-rheumatic drugs the disease can be well controlled in many...

    Authors: Nils Schubert, Tillmann Schill, Marlene Plüß and Peter Korsten
    Citation: BMC Rheumatology 2020 4:11
  22. The relationship between food and health is known since the antiquity and in the field of rheumatic and musculoskeletal diseases (RMDs), mainly rheumatoid arthritis (RA), a large number of studies has been pub...

    Authors: Alessia Alunno, Elena Nikiphorou, Elena Philippou, Claire Daien, Dieter Wiek, Marios Kouloumas and Maurizio Cutolo
    Citation: BMC Rheumatology 2020 4:10
  23. Despite high risk for cardiovascular disease (CVD) mortality, screening and treatment of hyperlipidemia in patients with rheumatoid arthritis (RA) is suboptimal. We asked primary care physicians (PCPs) and rhe...

    Authors: Iris Navarro-Millán, Anna Cornelius-Schecter, Ronan J. O’Beirne, Melanie S. Morris, Geyanne E. Lui, Susan M. Goodman, Andrea L. Cherrington, Liana Fraenkel, Jeffrey R. Curtis and Monika M. Safford
    Citation: BMC Rheumatology 2020 4:14
  24. Symptoms and comorbidities of ankylosing spondylitis (AS) considerably reduce health-related quality of life (HRQoL) and ability to work. This real-world study assessed rates of tumour necrosis factor inhibito...

    Authors: A. Deodhar, V. Strand, P. G. Conaghan, E. Sullivan, S. Blackburn, H. Tian, K. Gandhi, S. M. Jugl and R. Alten
    Citation: BMC Rheumatology 2020 4:19
  25. As awareness for the importance of mental health continues to expand in rheumatology, it is important to understand the epidemiology of psychiatric complications in ankylosing spondylitis (AS) with the ultimat...

    Authors: Jamie YE. Park, Alyssa M. Howren, Enav Z. Zusman, John M. Esdaile and Mary A. De Vera
    Citation: BMC Rheumatology 2020 4:12
  26. Black and Hispanic patients with osteoarthritis have more pain and worse function than Whites at the time of arthroplasty. Whether this is true for patients with rheumatoid arthritis (RA) is unknown.

    Authors: J. Hirsch, B. Mehta, J. Finik, I. Navarro-Millan, C. Brantner, S. Mirza, M. Figgie, M. Parks, L. Russell, D. Orange and S. Goodman
    Citation: BMC Rheumatology 2020 4:17
  27. Strategic drug therapy for rheumatoid arthritis (RA) patients with prolonged remission is not well defined. According to recent guidelines, tapering biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) ...

    Authors: Chayma Ladhari, Pierre Le Blay, Thierry Vincent, Ahmed Larbi, Emma Rubenstein, Rosanna Ferreira Lopez, Christian Jorgensen and Yves-Marie Pers
    Citation: BMC Rheumatology 2020 4:5
  28. Patients with rheumatoid arthritis (RA) have increased cardiovascular (CV) and mortality risk. Patients with RA are also frequently prescribed glucocorticoids (GCs) which have been associated with increased ri...

    Authors: Ruth E. Costello, Antonia Marsden, Mohammad Movahedi, Mark Lunt, Jenny H. Humphreys, Richard Emsley and William G. Dixon
    Citation: BMC Rheumatology 2020 4:4

    The Correction to this article has been published in BMC Rheumatology 2021 5:11

  29. Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are autoimmune disorders associated with an increased risk for depression, anxiety and sleeping problems. The objective of t...

    Authors: Philip Brenner, Anna Citarella, Louise Wingård and Anders Sundström
    Citation: BMC Rheumatology 2020 4:9
  30. Peripheral ulcerative keratitis (PUK) is a severe inflammatory ocular disease that can affect patients with a long history of rheumatoid arthritis (RA). The use of biotherapy has revolutionized the treatment o...

    Authors: Sara Benchérifa, Bouchra Amine, Imane El Binoune, Samira Rostom and Rachid Bahiri
    Citation: BMC Rheumatology 2020 4:6
  31. Joint replacements continue to occur during a rheumatoid arthritis (RA) patient’s lifetime despite significant advances in available treatment options. The purpose of this study was to examine and quantify syn...

    Authors: Evan A. Choate, Gurjit S. Kaeley, Jenny Brook, Roy D. Altman, John D. FitzGerald, Astrid R. Floegel-Shetty, David A. Elashoff and Veena K. Ranganath
    Citation: BMC Rheumatology 2020 4:8
  32. S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (D...

    Authors: Barbora Šumová, Lucie Andrés Cerezo, Hana Hulejová, Klára Prajzlerová, Michal Tomčík, Kristýna Bubová, Jan Štěpán, Mária Filková, Tereza Kropáčková, Mariam Grigorian, Karel Pavelka, Jiří Vencovský and Ladislav Šenolt
    Citation: BMC Rheumatology 2020 4:13
  33. Relapsing polychondritis (RPC) is a rare progressive autoimmune disease characterized by inflammation in the cartilage of multiple organs. Tracheobronchial involvement appears in nearly half of RPC patients du...

    Authors: Tomonori Makiguchi, Akira Koarai, Chihiro Inoue, Yayoi Aoyama, Taizo Hirano, Takashi Ohe, Tomohiro Ichikawa, Yutaka Shishikura, Hanae Komuro, Yoko Tsukita, Naoki Tode, Tadahisa Numakura, Tsutomu Saito, Teruyuki Sato, Yoshiya Mitsuhashi, Tsutomu Tamada…
    Citation: BMC Rheumatology 2020 4:1
  34. A definite diagnosis of gout requires demonstration of monosodium urate crystals in synovial fluid or in tophi, which in clinical practice today seldom is done. Dual energy CT (DECT) has repeatedly been shown ...

    Authors: Elin Svensson, Ylva Aurell, Lennart T. H. Jacobsson, Anton Landgren, Valgerdur Sigurdardottir and Mats Dehlin
    Citation: BMC Rheumatology 2020 4:7
  35. While total joint replacements (TJR) are frequently performed, there is little qualitative research to define the outcomes most important to patients.

    Authors: Susan M. Goodman, Bella Mehta, Serene Z. Mirza, Mark P. Figgie, Michael Alexiades, Jose Rodriguez, Peter Sculco, Michael Parks and Jasvinder A. Singh
    Citation: BMC Rheumatology 2020 4:3
  36. There are limited real-world data on the diagnostic experiences of patients with psoriatic arthritis (PsA), including medical care sought and potential barriers to diagnosis. We aim to describe patient experie...

    Authors: Alexis Ogdie, W. Benjamin Nowell, Eddie Applegate, Kelly Gavigan, Shilpa Venkatachalam, Marie de la Cruz, Emuella Flood, Ethan J. Schwartz, Beverly Romero and Peter Hur
    Citation: BMC Rheumatology 2020 4:2
  37. Treatment decisions for any disease are usually informed by reference to published clinical guidelines or recommendations. These recommendations can be developed to improve the relative cost-effectiveness of h...

    Authors: Sean P. Gavan, Gavin Daker-White, Katherine Payne and Anne Barton
    Citation: BMC Rheumatology 2019 3:47
  38. To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy.

    Authors: Arata Nakajima, Keiichiro Terayama, Masato Sonobe, Yasuchika Aoki, Hiroshi Takahashi, Yorikazu Akatsu, Junya Saito, Shinji Taniguchi, Manabu Yamada, Ayako Kubota and Koichi Nakagawa
    Citation: BMC Rheumatology 2019 3:48
  39. The Health Assessment Questionnaire-Disability Index (HAQ-DI) is used to assess functional status in rheumatoid arthritis (RA), but the change required for meaningful improvements remains unclear. A minimum cl...

    Authors: Frank Behrens, Michaela Koehm, Eva C. Schwaneck, Marc Schmalzing, Holger Gnann, Gerd Greger, Hans-Peter Tony and Harald Burkhardt
    Citation: BMC Rheumatology 2019 3:51
  40. The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Tissue repair responses include transforming growth factor beta (TGFβ)-induced myofibroblast production...

    Authors: Tue W. Kragstrup, Dong H. Sohn, Christin M. Lepus, Kazuhiro Onuma, Qian Wang, William H. Robinson and Jeremy Sokolove
    Citation: BMC Rheumatology 2019 3:46
  41. Patients with psoriatic arthritis (PsA) have increased risk of adverse events, including serious infections (SI), compared with psoriasis patients.

    Authors: Christopher T. Ritchlin, Mona Stahle, Yves Poulin, Jerry Bagel, Soumya D. Chakravarty, Shelly Kafka, Bhaskar Srivastava, Wayne Langholff and Alice B. Gottlieb
    Citation: BMC Rheumatology 2019 3:52
  42. RA flares are common and disabling. They are described in terms of worsening inflammation but pain and inflammation are often discordant. To inform treatment decisions, we investigated whether inflammatory and...

    Authors: Daniel F. McWilliams, Shimin Rahman, Richard J. E. James, Eamonn Ferguson, Patrick D. W. Kiely, Adam Young and David A. Walsh
    Citation: BMC Rheumatology 2019 3:49
  43. There is an ongoing discussion about incorporating additional risk factors to established WHO fracture risk assessment tool (FRAX) to improve the prediction accuracy in clinical subgroups. We aimed to reach an...

    Authors: Nicolas S. Bodmer, Hans Jörg Häuselmann, Diana Frey, Daniel Aeberli and Lucas M. Bachmann
    Citation: BMC Rheumatology 2019 3:50
  44. The prevalence of mood disturbances such as anxiety and depression is greater in rheumatoid arthritis (RA) patients than in the general population. Given this association, the primary aim of this study was to ...

    Authors: Steve Peterson, James Piercy, Stuart Blackburn, Emma Sullivan, Chetan S. Karyekar and Nan Li
    Citation: BMC Rheumatology 2019 3:43
  45. Work and workplace factors are important in fibromyalgia management. We investigated factors associated with sick leave in professionally active women living with fibromyalgia.

    Authors: F. Laroche, D. Azoulay, A. P. Trouvin, J. Coste and S. Perrot
    Citation: BMC Rheumatology 2019 3:44

Annual Journal Metrics

  • 2022 Citation Impact
    2.2 - 2-year Impact Factor
    2.9 - 5-year Impact Factor
    0.891 - SNIP (Source Normalized Impact per Paper)
    0.703 - SJR (SCImago Journal Rank)

    2023 Speed
    24 days submission to first editorial decision for all manuscripts (Median)
    247 days submission to accept (Median)

    2023 Usage 
    398,220 downloads
    294 Altmetric mentions 

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal